Advances in Therapy

, Volume 24, Issue 4, pp 907–920

Prognosis and treatment outcome in patients with acute myeloid Leukemia with t(8;21)(q22;q22)

  • Chih-Cheng Chen
  • Jyh-Pyng Gau
  • Yuan-Bin Yu
  • Chang-Hsien Lu
  • Kuan-Der Lee
  • Jie-Yu You
Article

DOI: 10.1007/BF02849984

Cite this article as:
Chen, CC., Gau, JP., Yu, YB. et al. Adv Therapy (2007) 24: 907. doi:10.1007/BF02849984

Abstract

Patients with acute myeloid leukemia (AML) with the t(8;21) karyotype generally have a favorable clinical course, but key prognostic factors remain poorly defined. This study was conducted to determine the prognoses and treatment outcomes of patients with AML with this unique cytogenetic change. A total of 22 patients with AML with t(8;21)(q22;q22) were studied. Various parameters were tested for their impact on disease-free survival (DFS) and overall survival (OS). Another 55 patients with AML with a normal karyotype were included for comparison of clinical outcomes. Between patients with t(8;21) and those with a normal karyotype, no significant differences were noted in DFS (median survival, 15.23 vs 12.03 mo;P=.7626) and OS (median survival, 19.17 vs 18.93 mo;P=.7543). Among t(8;21)(q22;q22) patients, no clinical parameters showed a significant impact on DFS. Univariate analysis revealed that a higher platelet count (> 15·109/L) at diagnosis, a low white blood cell count (index ≤20), and hematopoietic stem cell transplantation (HSCT) as postremission therapy were associated with improved OS. On multivariate analysis, HSCT as postremission therapy and white blood cell count index < 20 remained good independent prognostic factors for OS. The data presented here suggest that t(8;21)(q22;q22) cytogenetic changes in patients with AML had prognostic significance similar to that in patients with a normal karyotype; patients who harbored either karyotype had parallel clinical outcomes. It is concluded that patients with AML with t(8;21)(q22;q22) would be compromised by treatment approaches that do not include HSCT as postremission therapy.

Keywords

acute myeloid leukemiat(8;21)hematopoietic stem cell transplantationprognosis

Copyright information

© Springer Science and Business Media and LLC 2007

Authors and Affiliations

  • Chih-Cheng Chen
    • 1
  • Jyh-Pyng Gau
    • 2
  • Yuan-Bin Yu
    • 2
  • Chang-Hsien Lu
    • 1
  • Kuan-Der Lee
    • 3
  • Jie-Yu You
    • 4
  1. 1.Department of Medicine, Division of Hematology/Oncology Chang Gung Memorial Hospital-Chiayi Graduate Institute of Clinical Medical SciencesChang Gung UniversityTaoyuanTaiwan
  2. 2.Department of Medicine, Division of Hematology/Oncology Taipei Veterans General HospitalNational Yang-Ming University School of MedicineTaipeiTaiwan
  3. 3.Department of Medicine, Division of Hematology/OncologyChang Gung Memorial HospitalChiayiTaiwan
  4. 4.Department of Medicine, Division of Hematology/Oncology Lo-Tung Pohai HospitalNational Yang-Ming University School of MedicineTaipeiTaiwan
  5. 5.Lo-Tung Pohai HospitalLo-Tung, I-Lan CountyTaiwan